Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389287 | 1.00 | LRRK2 (0.62) | LRRK2PDGFRBRPS6KA3PSEN1PSEN2 | |
| SCHEMBL6389222 | 0.90 | SIRT1 (0.53) | LRRK2PDGFRBSIRT1MAP4K1 | |
| SCHEMBL6389227 | 0.90 | SIRT1 (0.53) | LRRK2PDGFRBSIRT1MAP4K1 | |
| SCHEMBL1538367 | 0.85 | KDR (0.59) | LRRK2PDGFRBRPS6KA3SIRT1RET | |
| SCHEMBL2768013 | 0.85 | KDR (0.59) | LRRK2PDGFRBRPS6KA3SIRT1RET | |
| SCHEMBL6390271 | 0.85 | RET (0.62) | PDGFRBRPS6KA3SIRT1RETMAP4K1 | |
| SCHEMBL6389448 | 0.85 | KDR (0.58) | PDGFRBRPS6KA3SIRT1RETMAP4K1 | |
| SCHEMBL6389451 | 0.85 | KDR (0.58) | PDGFRBRPS6KA3SIRT1RETMAP4K1 | |
| SCHEMBL6390272 | 0.85 | RET (0.62) | PDGFRBRPS6KA3SIRT1RETMAP4K1 | |
| SCHEMBL6403785 | 0.82 | SIRT1 (0.53) | LRRK2PDGFRBRPS6KA3SIRT1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| US-6680335-B2 | FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY | SUGEN, INC. | 2004-01-20 | — | — | US | claimed |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | claimed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6680335-B2 | FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY | SUGEN, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | LRRK2 526/4885PDGFRB 1860/4885RPS6KA3 188/4885 |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | PNCK, CAMK4, CAMK1 | LRRK2 81/4885PDGFRB 727/4885RPS6KA3 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.